Figure 4

Scenario and two-way sensitivity analysis. The impact of age at initiation of LAM resistance on the incremental cost-effective ratio (ICER) of rescue therapies in comparison with “no treatment” for LAM-resistant HBeAg-positive (A) and HBeAg-negative (B) chronic hepatitis B: the x-axis indicates the age at initial rescue therapy, the y-axis indicates the ICER ($ per additional QALY), the bold horizontal two-dash and solid lines represent the thresholds for China and Shanghai City, respectively. Varying the TDF cost and efficacy leads to different incremental cost-effective ratio (ICER) of TDF monotherapy over “no treatment” for LAM-resistant HBeAg-positive (C) and HBeAg-negative (D) chronic hepatitis B: the x-axis indicates the different cost of TDF, the y-axis indicates the different efficacy of TDF (the ratio relatively to the current using values in the base-case analysis), the bold oblique lines represent that the ICERs for TDF strategy were equal to combination strategy, and grey and white areas indicates the ICERs for TDF strategy were higher and lower than combination strategy, respectively. Combination strategy uses LAM and ADV.